The lymphoma program is dedicated to the care of patients with lymphomas at CBCI. The team focuses on providing state of the art management for lymphoma patients and offering novel research studies with its affiliation with the Sarah Cannon Research Institute.
We have a multidisciplinary approach involving close-working relationships with hematopathologists and radiologists to optimize delivery of treatment. We care for patients from initial diagnosis through to the management of more challenging cases that require specialized therapies. This may include hematopoietic stem cell transplant and cellular therapy, such as CAR T-cell therapy.
We have a multi-disciplinary approach involving close-working relationships with hematopathologists and radiologists to optimize your treatment.
Physicians at the Colorado Blood Cancer Institute (CBCI) are specialized experts in the care of lymphoma. From diagnosis to management and treatment, CBCI can assist you in helping you understand more about your type of lymphoma. CBCI participates in clinical research to improve treatment options and outcomes for patients.
There are two main lymphoma types: non-Hodgkin lymphoma and Hodgkin lymphoma. Yet, there are over 60 different types of lymphoma. Your treatment plan factors in the type of disease and the most up-to-date science.
Hodgkin lymphoma, also called Hodgkin disease, is a cancer originating from the immune system. The immune system is often found in lymphatic tissue. This includes lymph nodes and related organs (spleen, bone marrow, tonsils and thymus).
CBCI specializes in various consultations and treatments for patients with Hodgkin lymphoma.
Hodgkin lymphoma treatment
Prognosis and treatment options depend on a number of factors, including:
- Stage and type of Hodgkin lymphoma
- Blood test results
- Patient’s age, gender and general health
- Whether the cancer is aggressive
Hodgkin lymphoma can often be cured if found and treated early. Generally, patients with Hodgkin lymphoma are initially treated with medications, and sometimes radiation therapy is also employed.
The physicians at Colorado Blood Cancer Institute are experts at providing care suited to the unique needs of each patient. CBCI is also constantly studying new options to treat Hodgkin lymphoma to achieve the best outcomes for our patients.
Non-Hodgkin lymphomas (NHL) are a broad class of hematologic disorders of a certain type of white blood cell called lymphocytes. In NHL, the abnormal lymphocytes multiply and may be found in lymph nodes and related immune and blood-forming organs (spleen, bone marrow, tonsils and thymus). Types of non-Hodgkin lymphoma include:
B- Cell Lymphomas:
- Burkitt lymphoma
- Chronic lymphocytic leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Lymphoplasmacytic lymphoma (Waldenstrom Macroglobulinemia)
- Mantle cell lymphoma
- Marginal zone lymphomas
- Hairy cell leukemia
- Peripheral T-cell lymphoma
- Angioimmunoblastic T-cell Lymphoma (AITL)
- Anaplastic large cell lymphoma
- T-lymphoblastic lymphoma/leukemia
Physicians at CBCI are specialists in the diagnosis, management and treatment of patients with NHL, and work with providers throughout the region to assist in optimal care of patients with various types of NHL.
Non-Hodgkin lymphoma treatment
Prognosis and treatment options for NHL depend on a number of factors including:
- Stage and type of NHL
- Patient’s age and health
- Whether the cancer is slow growing or aggressive
Sometimes, active surveillance (also called a “watch and wait” approach) is recommended for certain lymphoid disorders. In others, medications are necessary early to control the disease.
Treatment options for NHL may also include radiation therapy. Depending on the type of NHL and how the disease acts, a cellular therapy option (such as stem cell transplant or CAR T-cell therapy) is indicated.
For some NHL, hematopoietic cell transplant using a patient’s own stem cells is recommended. These are called autologous stem cell transplants. In other NHL, patients have better outcomes when using a donor’s stem cells. These types of transplants are termed allogeneic stem cell transplants. Sometimes, a brother, sister, or even a parent or child may be the best donor for allogeneic transplants. Other treatments that may be indicated and available are called immune-based therapies. This includes bi-specific T-cell engagers (BITEs).
CBCI is a leader in innovative treatment options for patients with NHL and is always participating in and leading clinical research to improve treatment options and outcomes for patients. Should patients require cellular therapy, CBCI physicians and advanced practice providers remain the largest and most experienced in the multi-state region and continue to advance the field to benefit all patients.